While one study demonstrated that 89Zr-trastuzumab supports clinical decision making when HER2 status could not be determined by standard procedures (bone scan, 18F-FDG PET, CT and biopsy), the other study was able to determine tumor heterogeneity. Here, ERBB2 is linked to neoplasm.